PsyPal, the first consortium to receive an EU clinical research grant for the study of psychedelic therapy, has published a comprehensive guidance paper to inform stakeholders across research, clinical practice, regulation, policy, advocacy, and industry. The paper outlines key considerations…
The 2026 edition is co-developed by Ambassadors of the European Psychiatric Association (EPA) and European Society of Cardiology (ESC). The survey for mental health and cardiovascular health specialists was launched at the EPA-ESC Joint Symposium in Prague on Sunday, 29…
The EPA invites clinicians to take part in the TRUSTING Survey for Evaluating Risk of Relapse, launched today, Monday, 9 February. Clinicians practising in English, Czech, Dutch, French, German, or Turkish are kindly encouraged to answer this survey aiming to…
Prof. Andrea Fiorillo, EPA President, and Prof. Celso Arango, EPA President Elect presented the latest edition of the Headway – Mental Health Index 5.0 on “Care, Cohesion, and Growth: Advancing Mental Health through the Wellbeing Economy” at the European Parliament…
The EPA is pleased to share the Perspective on a Mentally Healthier 2035, a joint initiative of MIND, the Dutch Association of Mental Health and Addiction Care (de Nederlandse GGZ), the Netherlands Institute of Psychologists (NIP) and the Netherlands…
A European consortium of 19 partners has been awarded over €6.5M by the European Union to study psilocybin to treat psychological distress in people with progressive incurable illnesses requiring palliative care. This is the first time the EU has funded…